{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Worsening in severity of a reported adverse event should be reported as a new adverse', 'event. Laboratory abnormalities and changes in vital signs are considered to be adverse', 'events only if they result in discontinuation from the study, necessitate therapeutic', 'medical intervention, meets protocol specific criteria (see Section 6.1.8 regarding toxicity', 'management) and/or if the investigator considers them to be adverse events.', 'An elective surgery/procedure scheduled to occur during a study will not be considered an', 'adverse event if the surgery/procedure is being performed for a pre-existing condition and', 'the surgery/procedure has been pre planned prior to study entry. However, if the', 'pre-existing condition deteriorates unexpectedly during the study (e.g., surgery performed', 'earlier than planned), then the deterioration of the condition for which the elective', 'surgery/procedure is being done will be considered an adverse event.', 'All protocol-related AEs must be collected from the signing of the study specific informed', 'consent until study drug administration.', 'In addition, adverse events with onset or worsening reported by a subject from the time', 'that the first dose of study drug is administered until 70 days have elapsed following', 'discontinuation of study drug administration will be considered as treatment-emergent', 'adverse events.', '6.1.1.2', 'Serious Adverse Events', 'If an adverse event meets any of the following criteria, it is to be reported to AbbVie as an', 'SAE within 24 hours of the site being made aware of the SAE:', 'Death of Subject', 'An event that results in the death of a subject.', 'Life-Threatening', 'An event that, in the opinion of the investigator, would have', 'resulted in immediate fatality if medical intervention had not', 'been taken. This does not include an event that would have', 'been fatal if it had occurred in a more severe form.', 'Hospitalization or', 'An event that results in an admission to the hospital for any', 'Prolongation of', \"length of time or prolongs the subject's hospital stay. This\", 'Hospitalization', 'does not include an emergency room visit or admission to an', '77']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'outpatient facility or hospitalization for respite care.', 'Congenital Anomaly', 'An anomaly detected at or after birth, or any anomaly that', 'results in fetal loss.', 'Persistent or', 'An event that results in a condition that substantially interferes', 'Significant', 'with the activities of daily living of a study subject. Disability', 'Disability/Incapacity', 'is not intended to include experiences of relatively minor', 'medical significance such as headache, nausea, vomiting,', 'diarrhea, influenza, and accidental trauma (e.g., sprained', 'ankle).', 'Important Medical', 'An important medical event that may not be immediately life-', 'Event Requiring', 'threatening or result in death or hospitalization, but based on', 'Medical or Surgical', 'medical judgment may jeopardize the subject and may require', 'Intervention to', 'medical or surgical intervention to prevent any of the', 'Prevent Serious', 'outcomes listed above (i.e., death of subject, life-threatening,', 'Outcome', 'hospitalization, prolongation of hospitalization, congenital', 'anomaly, or persistent or significant disability/incapacity).', 'Additionally, any elective or spontaneous abortion or stillbirth', 'is considered an important medical event. Examples of such', 'events include allergic bronchospasm requiring intensive', 'treatment in an emergency room or at home, blood dyscrasias', 'or convulsions that do not result in inpatient hospitalization, or', 'the development of drug dependency or drug abuse.', 'For serious adverse events with the outcome of death, the date and cause of death will be', 'recorded on the appropriate case report form.', '6.1.1.3', 'Adverse Events Expected Due to SCLC or Progression of', 'SCLC', 'Adverse events that may be expected from primary SCLC lesions, compression of', 'adjacent thoracic structures or distant metastases are presented in Appendix J, Adverse', 'Events Expected Due to SCLC or Progression of SCLC of the protocol.', 'These adverse events may occur alone or in various combinations and are considered', 'expected adverse events in SCLC subjects.', '78']\n\n###\n\n", "completion": "END"}